Director/PDMR Shareholding

28 Mar 2007 16:41

VASTox plc28 March 2007 VASTox plc ("VASTox" or "the Company") DIRECTOR SHAREHOLDING Oxford, UK, 28 March 2007 - VASTox plc (AIM: VOX) announces that a total of8,807 Ordinary Shares of 10 pence per share were purchased today by three of theCompany's Non-executive Directors pursuant to the terms of the Non-executiveShare Ownership Scheme, which took effect on 1 February 2007 and was announcedon 27 March 2007. The details of the transaction are set out below: Director Number of Price Aggregate number of % of Ordinary Shares in shares Ordinary Shares issue beneficially owned purchased beneficially owned following the purchase following the purchaseBarry Price 2,077 £1.29 2,077 0.1%David Norwood 6,037 £1.29 6,037 0.1%Sir Brian Richards 693 £1.29 693 0.1% - ends - For more information, please contact: VASTox Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951Darren Millington, Chief Financial Officer Citigate Dewe RogersonMark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571 About VASTox plc VASTox is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced chemistry and drug screening (chemical genomics)technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. VASTox has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. VASTox's in-house drug development capabilities combine world-class expertise inboth medicinal and carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering datathat are highly predictive of the efficacy and toxicity of potential drugcompounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: VOX Further information about the company is available at www.vastox.com. This information is provided by RNS The company news service from the London Stock Exchange